Sarissa Capital Management LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001577524

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 10 positions · Total reported value $177.88M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 20.0% · 1 new · 1 cut · 0 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +16.0% · vs SPY +1.2% · Prev Value $157.64M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Sarissa Capital Management LP disclosed 10 equity positions with a combined reported value of $177.88M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were INVA ($42.94M), IRWD ($38.68M), AMRN ($26.67M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Sarissa Capital Management LP opened 1 new positions, trimmed 1 and fully exited 0, a turnover rate of 20.0% of positions. The portfolio's overlap with the prior quarter was 90% of names.

The largest new positions opened in Q2 2026 were BIIB ($205.26K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • BIIB BIOGEN INC COM · $205.26K

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Sarissa Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Sarissa Capital Management LP is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q2 2026 it reported 10 US equity positions with a combined value of $177.88M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-77926 (status: Approved), registered 2013-04-10
  • Regulatory AUM (Form ADV): $298.34M as of 2026-07-08
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 4 private funds, of which 4 hedge funds

Portfolio Structure

  • 10 positions · $177.88M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: INVA (INNOVIVA INC) at 24.1%
  • Average position size: $17.79M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 1 added, 1 reduced
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Sarissa Capital Management LP appears to maintain a conservative approach, with a focus on stability and steady growth in their holdings. The fund's actions suggest a preference for holding onto positions rather than making significant changes, reflecting a cautious market stance. 2. Key Moves: - Reduced: INVA (Innoviva Inc.) by 11.3%, indicating a possible reevaluation of the stock's potential. - Added: BIOHAVEN LTD (BHVN) by 3.4%, showing confidence in the company's prospects. - No Change: Most holdings, including IRWD (Ironwood Pharmaceuticals), AMRN (Amarin Corp PLC), NBIX (Neurocrine Biosciences Inc.), CYTK (Cytokinetics Inc.), LNTH (Lantheus Holdings Inc.), REGN (Regeneron Pharmaceuticals), VOR (VOR Biopharma Inc.), and BIIB (Biogen Inc.). - New Entry: BIIB (Biogen Inc.), indicating a new interest in the biotech sector. 3. Portfolio Structure: - Passive/Active: The fund seems to lean towards a passive strategy, with a few additions and no significant changes to most positions. - Sector Bias: A clear bias towards the healthcare sector, with 10 out of 10 holdings in this area. - Risk Appetite: The conservative nature of the holdings suggests a moderate risk appetite, with a preference for stable and established companies. 4. Per-Holding One-Liner: - INVA: Health care biotechnology (unverified) - IRWD: Specializes in gastrointestinal and urological products (unverified) - AMRN: Develops omega-3 fatty acid-based prescription drugs (unverified) - NBIX: Develops and commercializes neuroscience drugs (unverified) - CYTK: Biopharmaceutical company focusing on cellular therapies (unverified) - LNTH: Develops and commercializes medical imaging agents (unverified) - BHVN: Develops and commercializes biopharmaceuticals (unverified) - REGN: Biopharmaceutical company focusing on the development of therapies for a range of diseases (unverified) - VOR: Biopharmaceutical company focusing on rare and orphan diseases (unverified) - BIIB: Biotechnology company focusing on neurology, immunology, and hematology (unverified) 5. One-Sentence Style Summary: Sarissa Capital Management LP maintained a conservative healthcare-focused portfolio in Q2 2026, with a cautious rebalancing that saw minimal changes to holdings and a strategic addition to the biopharmaceutical sector.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 1.89M $42.94M 24.14%
24.14%
Reduce
2 9.19M $38.68M 21.75%
21.75%
Hold
3 1.67M $26.67M 15.00%
15.00%
Hold
4 116.53K $19.64M 11.04%
11.04%
Hold
5 228.62K $19.48M 10.95%
10.95%
Hold
6 166.92K $18.52M 10.41%
10.41%
Hold
7 582.31K $8.66M 4.87%
4.87%
Add
8 4.19K $2.61M 1.47%
1.47%
Hold
9 25.40K $467.60K 0.26%
0.26%
Hold
10 950 $205.26K 0.12%
0.12%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 100% R 90% F1 95% (modelled on 2026-Q1; 9/10 hit)

Historical Backtest (10 quarters)

Avg precision 96% · recall 95% · F1 95% · avg rank error 0.9 · Top-10 turnover 6%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 100% 90% 95% IRWD · BIIB · INVA · GILD · NBIX · AMRN · BCRX · VOR · RGLS IRWD · BIIB · INVA · GILD · NBIX · AMRN · CYTK · BCRX · VOR · RGLS
2024-Q2 100% 100% 100% IRWD · BIIB · INVA · GILD · NBIX · AMRN · CYTK · BCRX · VOR · RGLS BIIB · INVA · IRWD · GILD · CYTK · NBIX · AMRN · BCRX · VOR · RGLS
2024-Q3 90% 90% 90% BIIB · INVA · IRWD · GILD · CYTK · NBIX · AMRN · BCRX · VOR · RGLS INVA · IRWD · GILD · CYTK · NBIX · AMRN · BIIB · LNTH · VOR · RGLS
2024-Q4 80% 100% 89% INVA · CYTK · IRWD · GILD · NBIX · AMRN · BIIB · LNTH · VOR · RGLS INVA · IRWD · NBIX · CYTK · GILD · AMRN · LNTH · VOR
2025-Q1 88% 100% 93% INVA · IRWD · NBIX · CYTK · GILD · AMRN · LNTH · VOR INVA · NBIX · CYTK · IRWD · AMRN · LNTH · VOR
2025-Q2 100% 100% 100% INVA · NBIX · IRWD · CYTK · AMRN · LNTH · VOR INVA · NBIX · AMRN · CYTK · IRWD · LNTH · VOR
2025-Q3 100% 88% 93% INVA · NBIX · CYTK · AMRN · IRWD · LNTH · VOR INVA · NBIX · CYTK · IRWD · AMRN · LNTH · REGN · VOR
2025-Q4 100% 89% 94% INVA · NBIX · CYTK · IRWD · AMRN · LNTH · REGN · VOR INVA · IRWD · NBIX · CYTK · AMRN · LNTH · BHVN · REGN · VOR
2026-Q1 100% 100% 100% INVA · IRWD · NBIX · AMRN · CYTK · LNTH · BHVN · REGN · VOR INVA · IRWD · AMRN · NBIX · CYTK · LNTH · BHVN · REGN · VOR
2026-Q2 ★ 100% 90% 95% INVA · IRWD · AMRN · NBIX · CYTK · LNTH · BHVN · REGN · VOR INVA · IRWD · AMRN · NBIX · CYTK · LNTH · BHVN · REGN · VOR · BIIB

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Sarissa Capital Management LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Sarissa Capital Management LP reported 10 equity positions worth $177.88M in aggregate; its largest disclosed positions were INVA ($42.94M), IRWD ($38.68M), AMRN ($26.67M).

How large is Sarissa Capital Management LP's portfolio?

Sarissa Capital Management LP reported $177.88M of long equity holdings across 10 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Sarissa Capital Management LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/sarissa-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →